Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 93

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 93
---
 |
| ● | the timing and amount of sales of Renovaro Cube’s products, if any, and collection of related receivables;                                                                                                                     |
| ● | the extent to which Renovaro Cube’s products are eligible for coverage and/or reimbursement from third-party payors;                                                                                                           |
| ● | the emergence of new technologies or any competing tests, products, or services and other adverse market developments; and                                                                                                     |
| ● | other potential adverse developments.                                                                                                                                                                                          |

Risks Related to Renovaro Cube’s Business Operations, Products and Industry

Renovaro Cube’s products may not perform as expected, which could materially and adversely affect Renovaro Cube’s business, financial condition, results of operations and growth prospects.

Renovaro
Cube does not currently have a commercial product. Renovaro Cube’s success depends on the market’s confidence that it can
provide reliable, high-quality products. Assuming successful launch, Renovaro Cube’s products may not perform as expected.
If this were to occur, Renovaro Cube’s business, financial condition, results of operations and growth prospects would suffer.

Renovaro
Cube’s AI platform requires a number of complex and sophisticated biochemical and bioinformatics processes, many of which are highly
sensitive to external factors. An operational or technological failure in one of these complex processes or fluctuations in external variables
may result in sensitivity and specificity rates that are lower than Renovaro Cube anticipates or that vary between test runs or in a higher
than anticipated number of tests that fail to produce consistent results. In addition, Renovaro Cube regularly evaluates and refines its
algorithms and other processes under development. These refinements may inadvertently result in unanticipated issues that may reduce Renovaro
Cube’s sensitivity and specificity rates or otherwise adversely affect the performance of the tests supported by Renovaro Cube’s
AI platform and the results of such tests.

Further,
Renovaro Cube plans to iterate and improve, enhancing product performance, offerings, scalability and/or cost of goods. However, Renovaro
Cube may not be successful in transitioning its AI platform to a new or enhanced version or iteration. Product development involves a
lengthy and complex process and Renovaro Cube may be unable to commercialize, validate, or improve performance of any of its AI platform
or products on a timely basis, or at all. Renovaro Cube’s failure to successfully develop new and/or improved products (including
new versions of its existing platform and other products) on a